DrugBiological
Complement C1 Inhibitor Protein clinical trials
Also written C1 Esterase Inhibitor.
Includes 13 studies of Conestat alfa.
Keep track of what changes. Save the Complement C1 Inhibitor Protein studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
35 studies that test it; most in 2005 (5)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 4 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 17
Pharming Technologies B.V. (6) · Shire (5) · CSL Behring (4) · University Hospital, Basel, Switzerland (3) · IMMUNOe Research Centers (2) · Radboud University Medical Center (2) · Bernstein Clinical Research Center (1) · Universitaire Ziekenhuizen KU Leuven (1)
Often tested with
Tested in the same studies.
C1 esterase inhibitor (human) (4) · Antithrombin-III (1) · Antithrombin III (1) · Infliximab (1) · Apotransferrin (1) · Glutathione (1) · Melatonin (1) · Epoprostenol (1)
Studies
Open first, then newest update. How each study uses Complement C1 Inhibitor Protein is read from its arms, and is right about nine times in ten.
Testing it · 35
- Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)RecruitingPhase 2Haaglanden Medical CentreNCT06359782Written as C1 Esterase Inhibitor Injection [Cinryze]
- Safety and Efficacy of Conestat Alfa for ACE-Induced AngioedemaNot yet recruitingPhase 3University of CincinnatiNCT06679426Written as Conestat Alfa
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve ImplantationCompletedPhase 2University Hospital, Basel, SwitzerlandNCT05145283Written as Conestat alfa (Ruconest®)
- Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 InfectionCompletedPhase 2IMMUNOe Research CentersNCT04705831Written as Ruconest
- Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)CompletedPhase 4Bernstein Clinical Research CenterNCT06690047Written as Ruconest
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)CompletedPhase 2Universitaire Ziekenhuizen KU LeuvenNCT02251041Written as C1-Inhibitor
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedPhase 2Pharming Technologies B.V.NCT01359969Written as rhC1INH
- Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19CompletedPhase 2Pharming Technologies B.V.NCT04530136Written as Ruconest
- Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant RecipientsTerminatedPhase 3CSL BehringNCT03221842Written as C1-esterase inhibitor
- Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19TerminatedPhase 2University Hospital, Basel, SwitzerlandNCT04414631Written as Conestat alfa
- C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedPhase 3ShireNCT00289211Written as C1 esterase inhibitor [human] (C1INH-nf)
- C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedPhase 3ShireNCT01005888Written as C1 esterase inhibitor [human] (C1INH-nf)
- Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedPhase 3ShireNCT00438815Written as C1 esterase inhibitor [human] (C1INH-nf)
- Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedPhase 3ShireNCT00462709Written as C1 esterase inhibitor [human] (C1INH-nf)
- Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema SubjectsCompletedPhase 1ShireNCT00432510Written as C1 esterase inhibitor [human] (C1INH-nf)
- A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG InfusionsCompletedPhase 4IMMUNOe Research CentersNCT03576469Written as C1-esterase inhibitor [recombinant] (C1-INH-R)
- Research Into the Effect of a Clot-dissolving Agent and Its InhibitorTerminatedEarly Phase 1TSI, LLCNCT01694381Written as C1-inhibitor
- RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft FunctionStatus unknownPhase 1University of Wisconsin, MadisonNCT03791476Written as rhC1INH
- C1-inhibitor in Allergic ASThma PatientsTerminatedPhase 4T. van der PollNCT03051698Written as C1-inhibitor
- C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft RejectionCompletedPhase 2NYU Langone HealthNCT02936479Written as C1-INH (Berinert)
See all 35 studies that test Complement C1 Inhibitor Protein →
Codes
What other systems call Complement C1 Inhibitor Protein · ClinicalTrials.gg INT008866
- MeSH (NLM) D050718Complement C1 Inhibitor ProteinOne source ClinicalTrials.gov
- RxNorm 1599831One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D050718 | Complement C1 Inhibitor Protein | One source ClinicalTrials.gov |
| RxNorm | 1599831 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.